In irritable bowel syndrome, it is precisely this system that can be impaired.<\/p>\n
A systematic review of 66 studies showed that disruptions to the intestinal barrier were particularly common in patients with diarrhea-predominant irritable bowel syndrome (IBS-D) and following post-infectious irritable bowel syndrome. Depending on the study, 37 to 62 percent of IBS-D patients showed signs of impaired barrier function.<\/p>\n
When the gut environment becomes unbalanced, the microbiome, the barrier, and the immune system can negatively influence one another<\/h3>\n
![\"When](\"https:\/\/www.zeolith-wissen.de\/wp-content\/uploads\/2026\/08\/Darmmilieu-aus-dem-Gleichgewicht-Darmbarriere-Immunsystem.jpg\")
<\/p>\n
This explains why the gut can no longer be viewed today solely in terms of its bacteria. Rather, the microbiome, the gut environment, and the gut barrier form an interconnected system that even primary care physicians are increasingly paying attention to.<\/p>\n
Even when it comes to the microbiome, caution is warranted regarding simplistic cause-and-effect explanations. To this day, it is not always possible to determine whether certain microbial changes cause irritable bowel syndrome or whether the condition itself alters the microbiome – it\u2019s a classic chicken-and-egg scenario. In any case, research is showing more and more clearly that dysbiosis, immune activation, and barrier function are correlated.<\/p>\n
In fact, recent systematic scientific analyses have found not only changes in microbial composition in people with irritable bowel syndrome but also evidence of low-grade, yet chronic, immune activation. This gives rise to a biological model that is significantly more complex than the earlier notion of merely a \u201cnervous bowel.\u201d<\/p>\n
An adversely altered intestinal environment can influence the microbiome. Microbial metabolites, in turn, communicate with the intestinal epithelium (a thick layer of tissue lining the interior of the small and large intestines) and the immune system. If the barrier is simultaneously compromised, substances from the intestine can more easily come into contact with immune cells, which can lead to chronic overactivation of the immune system. This can thus give rise to numerous negative processes that perpetuate one another.<\/p>\n
All these findings have led to a new, fundamental question: In cases of irritable bowel syndrome, is it always necessary to add something to the gut\u2014or might it be just as sensible to remove something from it first?<\/em><\/strong><\/p>\n Studies show that reducing the intestinal load may be the right approach. Zeolites, by definition, are crystalline aluminosilicate minerals that occur naturally or are synthetically produced for industrial use. For medical applications, however, only natural clinoptilolite zeolite is of interest (see also: Clinoptilolite Zeolite<\/a>).<\/p>\n Its distinctive feature lies in its three-dimensional crystal structure. This structure forms a network of microscopically small channels and cavities and possesses ion-exchange and adsorption properties. Put simply, clinoptilolite can bind certain substances to its surface or within its accessible structure. In medicine, this mechanism of action is increasingly being utilized in the gastrointestinal tract.<\/p>\n In this respect, zeolite differs fundamentally from all other substances currently used to support gut health: Probiotics introduce selected microorganisms (whether these then actually remain in the gut is, incidentally, another question – see also: Zeolite and Probiotics: A Powerful Combination for Sustainable Gut Health<\/a>). Prebiotics are intended to serve as food for certain gut bacteria. Medicinal and plant substances are usually absorbed by the body and subsequently exert pharmacological or metabolic effects.<\/p>\n Clinoptilolite zeolite, on the other hand, acts locally only in the gastrointestinal tract and is not absorbed as a classic systemic active ingredient. So it doesn\u2019t add anything to the gut; rather, it removes something from it – that is, it relieves the gut, particularly of those substances and toxins that cause it significant distress, without the mineral interfering with metabolism. This is therefore a completely different approach, which could be loosely described as \u201ccleaning it out first instead of pouring even more in.\u201d<\/p>\n However, one aspect is of great relevance: not all zeolites are the same. Origin, purity, particle composition, processing, and quality control vary significantly among the multitude of zeolite products available on the market today. Furthermore, the results of scientific studies using a specific clinoptilolite preparation cannot therefore be automatically applied to just any other zeolite product. For this reason, almost all known clinical studies on zeolite focus exclusively on so-called \u201cPMA zeolite\u201d (see also: Zeolite – Recognizing Quality<\/a>).<\/p>\n PMA stands for \u201cpatented micro-activation\u201d and refers to a special processing method for natural, high-quality clinoptilolite developed by the research and development company PANACEO in Villach, Austria. Due to its physicochemical optimizations, this PMA zeolite has an even greater ability to bind certain undesirable substances. These include, for example, positively charged metabolic byproducts such as ammonium, various heavy metal ions – including lead, cadmium, arsenic, mercury, and nickel – and other toxins. All of these are substances to which humans are increasingly exposed – as evidenced by the high incidence rates of irritable bowel syndrome among younger people – due to changes in our environment.<\/p>\n Put simply, the mechanism of action of PMA zeolite results in a causal chain that is crucial for understanding its role in gut health:<\/p>\n Binding of undesirable substances \u2192 Relief of the gut environment \u2192 More favorable conditions for the microbiome and the gut barrier.<\/strong><\/p>\n It\u2019s important to be precise here: PMA zeolite does not \u201ccultivate\u201d good gut bacteria and is not a substitute for either prebiotics or probiotics. Rather, its approach comes one step before that. It can – as a foundation or fundamental tool, so to speak – help support the environment in which a healthy microbiome can thrive and a stable intestinal barrier can fulfill its protective function.<\/p>\n But what does this mean specifically for people with irritable bowel syndrome?<\/p>\n A study published in 2024 in the \u201cJournal of Gastroenterology\u201d addressed precisely this question. The study examined 204 patients with irritable bowel syndrome, including those with diarrhea-predominant IBS (IBS-D), constipation-predominant IBS (IBS-C), and mixed-type IBS (IBS-M). Over an eight-week period, the patients took PMA zeolite and documented, among other things, abdominal pain, bloating, stool frequency, and stool consistency. In addition, health-related quality of life was assessed.<\/p>\n The results were remarkable: Seven out of eight areas of quality of life improved significantly. Abdominal pain also decreased significantly, as did the number of days with bloating. Improvements were also observed in stool consistency – particularly among patients with diarrhea-predominant irritable bowel syndrome.<\/p>\n The study authors concluded that, under everyday conditions, PMA zeolite was able to alleviate overall IBS symptoms and improve stool consistency and disease-related quality of life. They explicitly classify PMA zeolite as a potential adjuvant – that is, supportive – measure for irritable bowel syndrome.<\/p>\n The clinical data available to date thus provide good reasons to take PMA zeolite seriously as a supportive measure for irritable bowel syndrome. The study involving 204 patients shows improvements in key symptoms and quality of life; further controlled studies are now needed to determine which patients benefit most and how significant the specific effect is.<\/p>\n In addition to the ever-increasing number of clinical studies on PMA zeolite – irritable bowel syndrome is just one of several conditions covered – there is now decades of experience from medical practice. According to surveys, approximately 85 percent of physicians who use PMA zeolite or recommend it to their patients (PMA zeolite is available under the name \u201cMed Darm Repair\u201d in every pharmacy and online) report an improvement in symptoms among their IBS patients, in some cases leading to complete remission.<\/p>\n What is therapeutically interesting about irritable bowel syndrome leads to the logical topic of prevention: After all, why should we only start paying attention to our gut once it is already diseased?<\/p>\n The intestinal barrier is one of the most important interfaces between the external environment and the body.<\/p>\n Day after day, it helps determine which substances are absorbed and which are kept out. A functioning barrier is therefore not only relevant for existing gut complaints but is also a fundamental prerequisite for health. This is where therapy and prevention converge.<\/p>\n Minimizing stress on the gut environment, supporting a stable gut barrier, and providing the microbiome with favorable living conditions are therefore not just concerns for people with irritable bowel syndrome. They are also increasingly part of modern preventive medicine and, ultimately, of healthy aging – so-called longevity.<\/p>\n PMA zeolite is not a panacea and does not replace a healthy diet, exercise, sleep, or medically necessary therapies. Its uniqueness lies rather in a comparatively simple mechanism of action: It acts where numerous stressors first encounter our body – in the gut. Whether as a supportive measure for existing intestinal problems or as a building block of a long-term preventive strategy aimed at maintaining health as much as possible before conditions such as irritable bowel syndrome develop, PMA zeolite is increasingly recognized scientifically as a causal component of modern prevention and therapy.<\/p>\n Studies and Sources:<\/span><\/p>\n Current systematic review on the gut microbiome in irritable bowel syndrome (2025)<\/span><\/p>\n \u201cAltered molecular signature of the intestinal microbiota in irritable bowel syndrome patients versus healthy controls: An updated systematic review.\u201d<\/p>\n This updated systematic review analyzed 44 studies in which the gut microbiota of people with irritable bowel syndrome was compared with that of healthy controls. Overall, IBS was associated with lower microbial diversity and an altered composition of various bacterial groups. Different changes were observed depending on the IBS subtype. At the same time, the authors emphasize that the exact relationship between these changes and the development or symptoms of irritable bowel syndrome has not yet been fully elucidated.<\/p>\n Link: https:\/\/pubmed.ncbi.nlm.nih.gov\/41413743<\/a><\/p>\n<\/div>\n Systematic Review on the Intestinal Barrier in Irritable Bowel Syndrome (2021)<\/span><\/p>\n \u201cIntestinal barrier dysfunction in irritable bowel syndrome: a systematic review.\u201d Therapeutic Advances. \u00bb<\/p>\n This large systematic review examined 66 studies on intestinal barrier function in IBS. Evidence of increased intestinal permeability was frequently found, particularly in diarrhea-predominant irritable bowel syndrome (IBS-D) and in post-infectious irritable bowel syndrome. In IBS-D, the prevalence ranged from 37 to 62 percent depending on the study, and in post-infectious IBS, it ranged from 17 to 50 percent. In IBS-C, such changes were much less common. The study thus also demonstrates that not every IBS patient has an impaired intestinal barrier.<\/p>\nZeolite: An ancient volcanic mineral with an unusual property<\/h3>\n
PMA zeolite binds substances that can burden the intestinal environment – this is where the crucial causal chain begins<\/h3>\n
204 IBS Patients: Clinical Study Shows Significant Improvements with PMA Zeolite<\/h2>\n
PMA Zeolite for Irritable Bowel Syndrome: A Supportive Measure Rather Than a Magic Bullet<\/h3>\n
From Irritable Bowel Syndrome to Prevention: Gut Health Begins Long Before Disease Sets In<\/h3>\n